Status:
UNKNOWN
Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia
Lead Sponsor:
Alen Greš
Conditions:
Cognitive Deficit
Eligibility:
All Genders
18-50 years
Phase:
EARLY_PHASE1
Brief Summary
Research goals: 1. Examination of the relationship between the use of vortioxetine and cognitive efficacy in patients with schizophrenia. 2. Examination of the association between the use of vortioxe...
Detailed Description
In the first phase of the research, the development of the research protocol and obtaining it will be done of his approval. The second phase of the research will include patients with schizophrenia d...
Eligibility Criteria
Inclusion
- age between 18 and 50, informed consent signed, confirmed diagnosis of schizophrenia, taking monotherapy with antipsychotics: aripiprazole, risperidone, paliperidone or olanzapine, unchanged dose maintenance back at least 6 months, remission of psychotic symptoms (PANSS ≤ 70), and that they do not have any of the exclusive criteria:
Exclusion
- taking benzodiazepines at doses equivalent to ≥ 10 mg diazepam, taking mood stabilizers, antidepressants three months ago, abuse of addictions back three months, suicide attempt back 6 months, suicidal, heteroaggressive, or other similar behavior back 6 months, somatic comorbidities affecting cognitive functions (intellectual disabilities, significant neurological disease or head trauma), pregnancy
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04456777
Start Date
July 1 2020
End Date
July 1 2022
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Centre Zagreb
Zagreb, Croatia, 10000